Video Interview

Under what conditions will the biotech sector as a whole return to the investor spotlight – regardless of when the corona pandemic is under control? Is a new wave of takeovers coming in 2022? Which new technologies and therapies are particularly exciting for BB Biotech? These and other questions are explored in an interview with Dr. Daniel Koller, Head of the Investment Team.